The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Randi Hernandez
Editor https://www.empr.com
Randi Hernandez is the oncology editor for Cancer Therapy Advisor. Randi has extensive experience in health care reporting and a particular interest in how medications shape the lives of patients and how treatments evolve, tracking them from scientific theory to clinical development, manufacturing stages, market release, and postmarketing studies. Prior to joining Haymarket, Randi held editing and/or writing roles at Pharmacy Times and Specialty Pharmacy Times, BioPharm International and Pharmaceutical Technology, Genetic Engineering and Biotechnology News (GEN), and BioPharma Dive.
